| Literature DB >> 27265685 |
Anna Krajczyk1, Joanna Zeidler1, Piotr Januszczyk1, Surendra Dawadi2, Helena I Boshoff3, Clifton E Barry3, Tomasz Ostrowski4, Courtney C Aldrich5.
Abstract
A series of 5'-O-[N-(salicyl)sulfamoyl]-2-aryl-8-aza-3-deazaadenosines were designed to block mycobactin biosynthesis in Mycobacterium tuberculosis (Mtb) through inhibition of the essential adenylating enzyme MbtA. The synthesis of the 2-aryl-8-aza-3-deazaadenosine nucleosides featured sequential copper-free palladium-catalyzed Sonogashira coupling of a precursor 4-cyano-5-iodo-1,2,3-triazolonucleoside with terminal alkynes and a Minakawa-Matsuda annulation reaction. These modified nucleosides were shown to inhibit MbtA with apparent Ki values ranging from 6.1 to 25nM and to inhibit Mtb growth under iron-deficient conditions with minimum inhibitory concentrations ranging from 12.5 to >50μM.Entities:
Keywords: 8-Aza-3-deazaadenosine; Adenylation inhibitor; Modified nucleoside; Siderophore biosynthesis; Tuberculosis
Mesh:
Substances:
Year: 2016 PMID: 27265685 PMCID: PMC4914392 DOI: 10.1016/j.bmc.2016.05.037
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641